Sign in to view content

Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

Jared S. Nielsen, MD, MBA

Video
Published 2022

Related

E27- DRCR Protocol V Results- Anti-VEGF vs Focal Laser vs Observation for DME in Eyes with Very Good Vision- Dr. Jennifer Sun
Keyvan Koushan, MD, FRCSC
Member Podcasts
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Updates from the Field
2021
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022

Category: AMD-Neovascular

See more